Radius Health, Inc. (NASDAQ:RDUS) management will conduct a conference call for 5th November 2020 at 8:30 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.radiuspharm.com
Earnings Expectation
Radius Health, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, RDUS to report 3Q20 loss of $ 0.21 per share. For the full year, analysts anticipate top line of $ 248.22 million, while looking forward to loss of $ 2.35 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 190.00 million ~ $ 220.00 million
Click Here For More Historical Outlooks Of Radius Health, Inc.
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
